Find It.
To cure cancer, it first must be found. Traxxsson has identified proprietary biomarkers for finding cancer.
Traxxsson’s BRE CancSure™ test resolves the dilemma of whether cancer is present when a woman has a positive mammogram. This simple blood test can determine that no cancer is present, thus ruling out the need for further testing in about 70% of patients with suspected breast cancer. Development of this test is nearing completion and it should be available in 2019.
Likewise, the Company’s LNG CancSure test can resolve the dilemma of whether lung cancer is present when a low-density CAT scan is positive. This rule-out test eliminates the need for further testing in >70% of people with positive lung scans – by establishing that the person does not have cancer.
Traxxsson’s long range goal is a single test to identify six of the most prevalent cancers. This test makes it economically feasible to do widespread screening for rarer, but deadly, cancers such as pancreatic or ovarian cancer.
Traxxsson’s BRE CancSure™ test resolves the dilemma of whether cancer is present when a woman has a positive mammogram. This simple blood test can determine that no cancer is present, thus ruling out the need for further testing in about 70% of patients with suspected breast cancer. Development of this test is nearing completion and it should be available in 2019.
Likewise, the Company’s LNG CancSure test can resolve the dilemma of whether lung cancer is present when a low-density CAT scan is positive. This rule-out test eliminates the need for further testing in >70% of people with positive lung scans – by establishing that the person does not have cancer.
Traxxsson’s long range goal is a single test to identify six of the most prevalent cancers. This test makes it economically feasible to do widespread screening for rarer, but deadly, cancers such as pancreatic or ovarian cancer.
|
|